More on gild
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $149.69 |
|
|||
| Open | $150.05 | ||||
| 52 Wk High | $108.63 | ||||
| 52 Wk Low | $71.39 | ||||
| Day High | $151.00 | ||||
| Day Low | $148.02 | ||||
| P/E | 83.39 | ||||
| EPS | $1.81 | ||||
| Volume | 5,284,287 | ||||
- Form 4 GILEAD SCIENCES, INC. For: Sep 22 Filed by: Burkhart Erin
- Form 4 GILEAD SCIENCES, INC. For: Sep 15 Filed by: Dickinson Andrew D
- Form 4 GILEAD SCIENCES, INC. For: Sep 15 Filed by: Mercier Johanna
- Gilead expands lenacapavir licensing to cover once-yearly HIV prevention
- Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention
- Form 144 GILEAD SCIENCES, INC. Filed by: Mercier Johanna
- Form 144 GILEAD SCIENCES, INC. Filed by: Dickinson Andrew D
- Gilead and PAHO agree on lenacapavir HIV prevention access in Americas
- Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean
- A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
Entities mentioned with gild
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Options | View Related Stories »
- Show More...
